A Phase I, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect.

Trial Profile

A Phase I, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2010

At a glance

  • Drugs AZD 3241 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2010 Actual patient number (77) added as reported by ClinicalTrials.gov.
    • 01 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top